A Phase 1 interventional study of ERUCOV-VAC and Placebo Vaccine in COVID-19 Vaccine, sponsored by Health Institutes of Turkey. Completed at 1 site in Turkey. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-02-14.
Sponsored by Health Institutes of Turkey · Phase 1, Interventional, and Prevention
The objective is to determine the safety and immunogenicity of two different strengths (3 µg and 6 µg) of an inactivated COVID 19 Vaccine compared to placebo so that to demonstrate the safety and efficacy in prophylaxis of COVID-19.
This is a double-blind, double dose, parallel, randomized vaccination study. Each subject will receive in random order a double intramuscular dose of ERUCOV-VAC 3 µg/0.5 ml Vaccine, ERUCOV-VAC 6 µg/0.5 ml Vaccine or 0.5 ml of placebo Vaccine according to a sequence determined by randomization, on Day 0 (1st vaccination) and Day 21 (2nd vaccination).In total 34 healthy subjects of both genders will be monitored for one year in total, after Day 43 the study will be unblinded and the volunteers who took placebo vaccine will be released from the study. The most important evaluation will be performed on Day 43 after the first vaccine dose.
7,640 studies on the registry are indexed under COVID-19; 488 are open to participants now.
This study's enrollment of 44 is below the median of 100 across 4,099 interventional studies indexed under COVID-19.
Browse COVID-19 studies →Health Institutes of Turkey is the lead sponsor of 18 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Type: Biological/Vaccine Name: ERUCOV-VAC 3 µg/0.5 ml Vaccine Intervention Description:Two applications on Days 0 and 21
Biological: ERUCOV-VAC
Type: Biological/Vaccine Name: ERUCOV-VAC 6 µg/0.5 ml Vaccine Intervention Description: Two applications on Days 0 and 21
Biological: ERUCOV-VAC
Placebo Vaccine, containing 0.9 % saline Intervention Description: Two applications on Days 0 and 21
Other: Placebo Vaccine
Vaccination on Day 0 and Day 21
Placebo Vaccination on Day 0 and Day 21
To assess the safety and tolerability of the COVID-19 vaccine
The number and proportion of subjects with adverse events observed until Day 43 post 1st vaccination are declared to be primary target variables.
Time frame: 43 days
Serum IgG antibody Levels
Serum IgG antibody levels specific for the SARS-CoV-2 rS protein antigen(s).
Time frame: 12 months
Neutralizing Antibodies Levels
Serum Neutralizing antibody levels.
Time frame: 12 months
TNF-alpha Levels
Serum TNF-alpha levels.
Time frame: 12 months
Interferon Levels
Serum IFN-γ levels.
Time frame: 12 months
Interleukine Levels
Serum IL-2, -4, -5, -6 levels.
Time frame: 12 months
Plan to share: No
This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Health Institutes of Turkey